Page 819«..1020..818819820821..830840..»

A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness – The Shepherd of the Hills Gazette

Posted: November 28, 2020 at 3:55 pm

Detroit Lions Senior VP of business development Kelly Kozole works with her daughter, Morgan, who has a rare neurological disorder called beta-propeller protein-associated neurodegeneration, or BPAN.Michael Rothstein

TROY, Mich. Wearing a white T-shirt with a massive star in sparkling shades of pink, yellow and seafoam green on the front, Morgan Kozole sits in front of a fold-up chalkboard in the living room of her familys Detroit-area home and starts to draw.

Using pink and yellow chalk, she sketches Mickey and Minnie Mouse. The Disney characters are dominant fixtures in the 5-year-olds life and therefore become a soundtrack for the Kozole family: Morgan constantly saying Mickey, with her long, blond ponytail bouncing to whatever song happens to be playing on the Mickey Mouse Club.

These are the two Mickeys, Morgan says, pointing to the chalkboard. Her mother, Detroit Lions senior vice president of business development Kelly Kozole, explains that this is her way of communicating that she would like a visitor to draw Mickey too. If its close, Morgan accepts it. Another Mickey to fawn over.

For Morgans birthday earlier this year, the family went to Disney World. On this trip, the Kozoles saw what they had longed for: the potential of progress.

She knew where we were. She knew Mickey Mouse, Kelly said. Before, she wouldnt go to the characters, and now shes jumping up and down, hugging. She really, along those lines, is also really into birthdays.

2 Related

The Happy Birthday song. Before that, she was just kind of looking. Sometimes it was too much for her with everyone singing sometimes loud noises are too much. This year, we had to sing Happy Birthday to her three times.

Birthdays, for children, are happy occasions reasons for grand celebrations of progress toward adulthood. For the rest of Morgans family it is more complicated.

Morgan has a rare neurological disease called beta-propeller protein-associated neurodegeneration, known as BPAN. Its a disorder, more prevalent in girls than boys, that causes delayed development and seizures, communication issues and, sometimes, motor dysfunction. Its unclear exactly how many people are living with BPAN worldwide due to its rarity, although Dr. Sami Barmada, a scientist at the University of Michigan studying BPAN, said a rough estimate is about 500 to 600 people.

Its rare enough that Dr. Henry Paulson, the director of the Michigan Alzheimers Disease Center, said there are experts in neurodegeneration who are unfamiliar with BPAN. While Kelly is trying to advocate for her daughter and others with BPAN through fundraising for research, science only moves so fast.

The Kozoles understand that. So birthdays for the family arent always happy. They are a reminder of what could come.

That ticking time clock, Kelly said. Every birthday isnt exciting for me for her. Because its one year closer to when this bomb is going to go off.

BPANs rarity makes the reality heartbreakingly simple: There are very few effective treatments, little research and no cure. As Morgan learns how to organize her Peppa Pig characters and learns new words on her iPad her future looms.

At some unpredictable point in Morgans teen and adult years the average is around age 25, according to Barmada development will just stop. Progress will decline and, in some cases, disappear. Those afflicted with BPAN begin suffering from progressive dystonia parkinsonism making it difficult to walk, talk or stand.

Any day, Kelly said, it could be like, Oh, your daughters gone.'

WHEN MORGAN WAS born on Jan. 12, 2015, she was, largely, a healthy baby. She was a little jaundiced but nothing worrisome.

When she would go to the doctors office for shots, Morgan didnt cry. It was a little abnormal, but when youre a parent of a young child no crying is viewed as a minor miracle. Kelly and her husband, Kevin, took this as a sign of a tough kid. Nurses even said how great it was.

Looking back, it was a warning sign something was wrong. BPAN causes a high pain tolerance. Before long, more concerns popped up. Morgan wasnt crawling at nine months, wasnt walking at a year. Expected milestones passed without Morgan reaching them. Kevin and Kelly put her in therapy in late 2016 to work up to these childhood progressive traits and began researching potential causes. They wouldnt find an answer for more than two years.

Morgan Kozole suffers from BPAN, a rare neurological disorder, but still loves the same things any 5-year-old would, including the iPad and her favorite character, Peppa Pig.Michael Rothstein

She was diagnosed with cerebral palsy at first. One doctor diagnosed her with that, and then another, our neurologist said she doesnt have that, Kelly said. Then there was speculation but not a full diagnosis she had autism, so we did all the tests for that.

So through this kind of journey of trying to find out what was wrong, it was exciting that she didnt have something that you were going to this test for but you still had so many more questions as you were eliminating all these potential diseases that she could have.

Befuddled, they began genetic testing, and in November 2018 received a letter about a mutation on Morgans WDR45 gene. Kelly Googled it, stumbled upon BPAN and freaked out, calling their neurologist. The neurologist told Kelly not to worry BPAN was very rare, and Morgan didnt have it.

Doctors diagnosed her with epilepsy because of seizures. Morgan took Keppra, which helped accelerate her vocabulary to about 50 words, typical for a 1-year-old, when she was 3. Then doctors said, no, it wasnt epilepsy, either.

Heres how the postseason bracket looks at the moment and what scenarios lie ahead. Playoff picture (ESPN+) Playoff Machine: See scenarios Standings | Football Power Index

Another meeting with another neurologist led to a different diagnosis. Three days after she and Kevin returned to Michigan from Super Bowl LIII in February 2019, they received a call. Doctors figured out what was wrong.

It was BPAN.

In my mind, its worse than cancer, Kelly said. How is this even possible? That this can even be so painful for kids later on in life. You try so hard to gain all these abilities, and then early adolescence or early adulthood, its just [gone] one day, and Ive seen a lot of these stories.

Theres a BPAN Facebook website, and thats where the doctors sent us. Theres no cure. Theres no therapy. Go to this website. Thats what I was told.

FOR MONTHS KELLY cried, angry and heartbroken. The Kozoles initially told their families and no one else.

In May 2019, Kelly went to her first Neurodegeneration with Brain Iron Accumulation (NBIA) conference. She met other parents, heard their stories and began the new normal.

She used her skills organization, fundraising and business to brainstorm ways to help. Hardly anyone researched BPAN. Without it, there would be no chance for a cure not in Morgans lifetime, which could reach her 40s, and not in the lifetime of those who might come after.

Kevin Kozole, husband of Lions senior VP Kelly Kozole, plays with his daughter, 5-year-old Morgan, who suffers from a rare neurological disorder called BPAN.Michael Rothstein

She shared what was happening with her boss, Detroit Lions president Rod Wood, and his wife, Susan, using a website link to explain BPAN. Wood knew something was wrong because of texts and emails saying they had to take Morgan to this specialist or that appointment.

As that was confirmed and became her reality, she is now able to talk about it in a way, Wood said. Because shes full bore on trying to help generate awareness and financial resources to find a cure for it.

She went from the unknown to the very tragic known to, OK, what are we going to do about it?'

Kelly consulted her aunts, both of whom worked in medicine. Linda Narhi worked in biotechnology for Amgen for more than 30 years; Dr. Diane Narhi was the first female chief of staff at Simi Valley (California) Hospital. From talking with another group of fundraising BPAN parents BPAN Warriors Kelly found a guide.

Any day, it could be like, Oh, your daughters gone.'

Kelly Kozole, Senior VP of Business Ops, Detroit Lions

If her aunts had not been resources, she might have joined BPAN Warriors. But Kelly admittedly needs to be in control, and this was her daughter. She needed to manage this herself. She created a nonprofit called Dont Forget Morgan.

Kellys aunts provided guidance, and Wood offered contacts he had in the finance industry and Silicon Valley. Wood and Lions general counsel Jay Colvin sit on the board. Other Lions coworkers with Woods blessing built the website, designed the logo and created social media plans and the first pitch video for Dont Forget Morgans rollout in 2020.

Everything you need this week: Full schedule | Standings Depth charts for every team Transactions | Injuries Football Power Index rankings More NFL coverage

Progress started with a $15,000 grant to help with a mouse model study at Sanford Research in South Dakota with another, larger, potential grant to come. In recent months, Kelly has focused largely on fundraising, and another parent of a child with BPAN, Christina Mascarenhas Ftikas, has focused on the medical side of the nonprofit.

This is why Im here, Kelly said. Im supposed to be a vehicle to get all of this awareness and hopefully a cure for BPAN so the child one, two, three, five years from now, there is hope.

There is no, Go to Facebook. There is something where you can actually give a parent, Heres the symptoms to look for.'

ABOUT AN HOUR away in Ann Arbor, Michigan, Kaci Kegler and her husband, Brian, had been in the same Facebook community. Kelly, new to the group and looking for a nearby connection, wrote Kaci a message.

Hey, my daughter was just diagnosed, could we connect?

Kaci understood. She did the same thing, reaching out without success in 2016 after her daughter, Elle, was diagnosed. Kaci wanted to be a resource.

They talked for an hour. There wasnt much Kaci could say to soothe her. Kelly pinged a year later with another message: Im starting a non-profit. Kaci offered to help.Despite suffering from BPAN, Morgan is like any other 5-year-old who enjoys playing with her brother, Connor.Michael Rothstein

Days later, on Feb. 28, Kaci and her husband, Brian, an assistant athletic director for development at the University of Michigan, had their yearly fundraiser for BPAN research on Rare Disease Day at Pizza House in Ann Arbor. They met a doctor who had a connection to researchers at Michigan.

I literally came home and texted [Kelly] and was like, Oh my gosh, we may have inroads, Kaci said. We just started texting. I have never met Kelly face-to-face. We still havent. But weve texted a lot and weve emailed quite a bit.

It just kind of started.

By summer, they went from nothing to putting pieces in place for a full-fledged research project with a two-year, $140,000 grant for Barmada and Dr. Jason Chua to help start to solve BPAN.

Chua was working on the regulation of autophagy, which is the cleaning out of damaged cells, and studying BPAN became a natural extension of the work he had already been putting in. BPAN alters that in neurons. Barmada said Chuas research provided a rare win-win situation to potentially help with BPAN and other diseases, too.

There are a set of questions in BPAN that nobody has the answer to, Barmada said. And Jason and myself, we just seem to be in the right position, the right place to be able to help out.

The goal is to understand what is happening within BPAN itself and how people end up with it while also trying to find therapies for existing patients. Within a year, they are hoping to grow stem cells from people with BPAN in their lab, allowing for the creation of their own stem cells missing the WDR45 gene. Then, they will try to either replace the gene or stimulate autophagy through genetic or pharmacologic means, Barmada said. The hope is this can prevent neurodegeneration.

So far, theyve hired a research assistant to work with Chua, developed tools to manipulate the gene using the genome-editing tool CRISPR and applied for approval from Michigan and the institutional review board to get skin biopsies to obtain stem cells from BPAN patients.

Its a process, but its also a start.

Lions VP tries to save daughter from rare disease Fantasy fallout: Keep rolling with rookies? Tuas benching a lesson for young QBs Big Ben making push for first MVP award Should Chiefs worry about pass-rush woes?

Since partnering with Michigan and Sanford, Dont Forget Morgan also began working with Dr. Kathrin Meyer, a researcher at the Center for Gene Therapy at Nationwide Childrens Hospital at Ohio State.

Solving this disease is going to require more than Jason and Sami, Paulson said. Its going to be a first shot across the bow, but its going to require more than that. Ill say this being in the field for a long time. Scientists who are coming up the pike say they want to look at Alzheimers, want to look at epilepsy. They dont say, I want to look at a rare disease.

The only way to solve a rare disease is to get someone hooked. Sometimes when you hook a really good one, as I think we have with Jason here, you hook them for life and they make a difference.

MORGAN IS BOUNCING around the Kozoles suburban Detroit home on this late August day. They just returned from northern Michigan, and having two kids, especially one with special needs, makes tidiness unrealistic.

COVID-19 changed things. Morgan hadnt been to many of her therapies for months. Online school barely kept her attention. There was concern she would have regression in her learning. Instead, her speech advanced by being around Kelly, Kevin and her older brother, Connor, all day. She has sung more songs recently to help increase her vocabulary. Sometimes, shell listen 20 times in a row.

Even more than that, Connor said. They arent sure how much shes truly learning versus memorization. But it is something.Morgan Kozole has inspired her mother, Detroit Lions VP Kelly Kozole, to marshal researchers and other advocates to develop a cure for BPAN, and perhaps help future generations of children who live with the disorder.Michael Rothstein

The family gathers inside Morgans bedroom complete with a special Haven Bed with a zipper to keep her safe from wandering around at night, when she could accidentally turn on the stove and hurt herself or others as sleep disorders are another BPAN issue. She sits on the floor and starts playing with her small, yellow dollhouse and a fake ice cream maker. Kelly asks for an ice cream. Morgan makes one for herself instead and pretends to eat it.

Later, outside, Morgan kicks a soccer ball and plays a modified game of catch with a squishy football. Football, no surprise, is big. She says hike a lot. She knows that term, Kevin says, laughing.

In these moments, Morgan seems like any other young child. She attends St. Hugo of the Hills Parish School in Bloomfield Hills, Michigan, but has a one-on-one para nanny to help. She interacts with people, often overly affectionate.

Sitting at the kitchen table after playtime outside, she plays with Starfall, a childrens learning app, on her iPad. They hope it accelerates her word recognition. Morgan is entranced watching Farmer in the Dell and using her hands to eat orange slices and Cheerios. She needs a mirror in front of her to provide her a target for her mouth. She listens to books, another way to try absorbing information.

Morgan can now count to 20 and say three sentences in a row. Kelly and Kevin have tried to give Morgan a normal life in an abnormal situation, but they worry about the future what she wont have and wont be able to experience.

But Morgan has changed some of that outlook, too.

Focus on how she is so loving and has so much pure joy. A lot of parents of special needs [kids] say you can learn so much from these kids, and you really can, Kelly said. She is, every morning, just so happy, and Mama! Hugs and kisses to strangers. She has none of those behaviors you learn as an adult where youre not kind to people or you dont want to talk to someone.

She is just open arms, will give you a hug and is so loving, and its like, Wow, this is really what life is about.'

Read the rest here:
A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness - The Shepherd of the Hills Gazette

Posted in Ohio Stem Cells | Comments Off on A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness – The Shepherd of the Hills Gazette

Ash 2020 cell therapy preview the battle for recognition – Vantage

Posted: November 27, 2020 at 9:49 am

The Ash conference is usually a mecca for cell therapy followers. Its 2020 instalment features plenty of Car-T and Car-NK presentations, though investors might rue the fact that these risk being overshadowed by antibody modalities.

Clinical data to watch on adoptive cell therapies include those on Fates allogeneic Car-NK project FT596 and Celyads Cyad-02, a Car using short hairpin RNA technology. Meanwhile, Allovir will want to justify enthusiasm for its recent flotation, whileBCMA-targeted multiple myeloma assets fight to stand out from the crowd.

The most advanced anti-BCMA Car-T therapy is Bristol Myers Squibb/Bluebirds ide-cel, which faces a March 27, 2021 US FDA action date despite an earlier refuse-to-file letter. The asset to watch, however, is Johnson & Johnson/Legend Biotechs cilta-cel, whose Cartitude-1 study is showing a remarkable 95% remission rate, according to the Ash abstract.

Not only that, but Bristol/Bluebirds follow-up, bb21217, looks disappointing, Ash data suggest. A US NCI group including Dr James Kochenderfer, who has also worked on ide-cel, is separately presenting clinical results on a new approach, FHVH-BCMA-T, which uses a heavy chain antibody fragment rather than the normal scFv.

With most abstracts citing relatively early data cut-offs, updates at Ash itself will be keenly awaited. Among these Poseida will no doubt field questions if responses to P-BCMA-101 continue to lookbetter at low than at high doses.

Long time coming

First clinical data on FT596, Fates first Car-modified NK cell approach, have been a long time coming: the FDA signed off the IND in September 2019, but the trial did not start until April this year.

Even so there might be disappointment as the Ash abstract details only a single case study, in a lymphoma subject who went into partial response after a single dose. Expectations for FT596 are high given the 73% response rate cited for an unrelated anti-CD19 Car-NK project run by MD Andersons Dr Katy Rezvani.

There might be more on FT596 at Ash, but some analysts are reining in expectations of meaningful data before next year. In the unmodified NK cell sphere, meanwhile, FC21-NK data could support Sanofis decision to buy Kiadis for $358m this month.

Celyad has been working on Car-T cells targeting NKG2D ligands for some time, but Ash will feature the first clinical data on Cyad-02, a construct that aims to improve on an earlier iteration, Cyad-01.

One problem with Cyad-01 is Car-T fratricide, caused by T cells' own transient expression ofNKG2D ligands; Cyad-02 aims to silence these ligands using shRNA technology. The Ash abstract says Cyad-02 showed threefold better expansion than Cyad-01, and promises to deliver preliminary clinical activity data.

While Cyad-02 is an autologous therapy, Celyad is separately developing allogeneic Cars. One of its allogeneic approaches also usesshRNA for gene silencing, so the Cyad-02 data could provide proof of concept beyond the use in the abstract.

Allogeneic therapies will of course be aired extensively at Ash, and a presidential symposium on 8 December will see UCLAs Dr Gay Crooks discussing universal cell sources. Dr Crookss pluripotent stem cell generation technology was licensed to Kite before that company was bought by Gilead.

Other presentations of general interest include a paper suggesting that CD5 knock-out enhances Car-T cell activity, and another claiming that aberrations in CD58 curtail the efficacy of Yescarta. The latter is also being highlighted at a December 5 press briefing, along with preclinical data on Allovirs anti-Covid-19 T-cell therapy ALVR109.

Investors in Allovir, whose stock has doubled since the group raised $318m in a July IPO, will pay close attention.

Ash 2020 will take place in virtual format on December 5-8.

Vantage analysis previously summarised upcoming Ash presentations that resulted in early share price moves, cancer-focused abstracts outside cell therapy, and those in non-oncology indications.

Originally posted here:
Ash 2020 cell therapy preview the battle for recognition - Vantage

Posted in Cell Therapy | Comments Off on Ash 2020 cell therapy preview the battle for recognition – Vantage

New ‘smart’ cell therapies show promise in solid tumours – Drug Target Review

Posted: November 27, 2020 at 9:49 am

By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.

Researchers working to identify anti-cancer therapeutics that can selectively target tumour cells without damaging normal cells have used machine learning and therapeutic cell engineering to develop smart cell therapies for solid tumours.

The research is split across two papers, in the first published in Cell Systems researchers in the lab of Dr Wendell Lim at the University Of California San Francisco (UCSF) Cell Design Initiative and Center for Synthetic Immunology, both US, teamed up with a group of computer scientists led by Dr Olga Troyanskaya at Princeton Universitys Lewis-Sigler Institute for Integrative Genomics and the Simons Foundations Flatiron Institute.

The scientists used computational approaches to examine the gene expression profile of more than 2,300 genes in normal and tumour cells to see what antigens could help discriminate between diseased and healthy cells. They then used machine learning techniques to come up with antigen combinations and determined if they could significantly improve how T cells recognise tumours while ignoring normal tissue.

Following the identification of antigen combinations on the computer, they engineered T cells to target them using a system known as synNotch. synNotch is a customisable molecular sensor that allows synthetic biologists to fine-tune the programming of cells and was developed in the Lim lab in 2016. According to the team it is a receptor that can be engineered to recognise a myriad of target antigens; additionally the response of synNotch to a target antigen can also be programmed, meaning the therapeutic T cell can execute any of a range of responses once an antigen is recognised.

They specifically used synNotch to programme T cells to destroy kidney cancer cells that express a unique combination of antigens called CD70 and AXL. Although CD70 is also found in healthy immune cells, and AXL in healthy lung cells, the engineered T cells killed only the cancer cells and spared the healthy cells.

The field of big data analysis of cancer and the field of cell engineering have both exploded in the last few years, but these advances have not been brought together, said Troyanskaya. The computing capabilities of therapeutic cells combined with machine learning approaches enable actionable use of the increasingly available rich genomic and proteomic data on cancers.

In the second paper, published inScience, Lim and colleagues used their computationally derived protein data to design effective and highly selective cell therapies for cancer.

Currently, most cancer treatments, including cell therapies, are told block this or kill this,' said Lim, also professor and chair of cellular and molecular pharmacology and a member of the UCSF Helen Diller Family Comprehensive Cancer Center. We want to increase the nuance and sophistication of the decisions that a therapeutic cell makes.

The researchers highlighted the example of chimeric antigen receptor (CAR) T cells. In CAR T-cell therapy, T cells are collected from a patient and manipulated in vitro to express a receptor that will recognise a specific antigen on cancer cells. However, despite their success in haematological malignancies like leukaemia and lymphoma, so far, the method has not been as effective in solid tumours. Cells in these cancers often share antigens with normal cells found in other tissues and they also create an immunosuppressive microenvironment; both limit the efficacy of CAR T cells.

Lim said that since solid tumours are more complex than blood cancers, a more complicated product is required to combat them.

In their paper, researchers daisy-chained multiple synNotch receptors together to create a host of complex cancer recognition circuits. The team said that since synNotch can activate the expression of selected genes in a plug and play manner, these components can be linked in different ways to create circuits with diverse functions, allowing for precise recognition of diseased cells and a range of responses when those cells are identified.

This work is essentially a cell engineering manual that provides us with blueprints for how to build different classes of therapeutic T cells that could recognise almost any possible type of combinatorial antigen pattern that could exist on a cancer cell, noted Lim.

The team gives two examples of how this can function:

In the paper the team uses these configurations to selectively kill cells carrying different combinatorial markers of melanoma and breast cancer. They also showed in a murine model of two similar tumours with different antigen combinations, that the T cells efficiently and precisely located and killed the tumour they had been engineered to detect.

Lims group is now exploring how these circuits could be used in CAR T cells to treat glioblastoma.

Related topicsBioengineering, Biologics, Disease research, Drug Development, Drug Targets, Immunooncology, Immunotherapy, Protein, Proteomics, Screening, Therapeutics

Excerpt from:
New 'smart' cell therapies show promise in solid tumours - Drug Target Review

Posted in Cell Therapy | Comments Off on New ‘smart’ cell therapies show promise in solid tumours – Drug Target Review

Autologous Cell Therapy Market 2020-2024- Featuring Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., Among Others | Industry…

Posted: November 27, 2020 at 9:49 am

LONDON--(BUSINESS WIRE)--The autologous cell therapy market is poised to grow by USD 1.97 bn during 2020-2024 progressing, at a CAGR of almost 22% during the forecast period.

Worried about the impact of COVID-19 on your Business? Here is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.

Get FREE Sample Report in Minutes!

The report on the autologous cell therapy market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the use of biomass as a fuel in boilers.

The autologous cell therapy market analysis includes the therapy segment, application segment, and geography landscape. This study identifies the increasing demand for effective drugs for cardiac and degenerative disorders as one of the prime reasons driving the autologous cell therapy market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The autologous cell therapy market covers the following areas:

Autologous Cell Therapy Market Sizing

Autologous Cell Therapy Market Forecast

Autologous Cell Therapy Market Analysis

Companies Mentioned

Related Reports on Health Care Include:

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Therapy

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendors covered

Appendix

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See the article here:
Autologous Cell Therapy Market 2020-2024- Featuring Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., Among Others | Industry...

Posted in Cell Therapy | Comments Off on Autologous Cell Therapy Market 2020-2024- Featuring Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., Among Others | Industry…

For Research Only Creative Biolabs Stem Cell Therapy Development Solutions – Press Release – Digital Journal

Posted: November 27, 2020 at 9:49 am

For over a decade since establishment, Creative Biolabs provides exclusive one-stop services in a systematic manner to global clients to support their RESEARCH on stem cell therapy that has great medical prospects.

New York, USA - November 27, 2020 - Stem cells are non-specialized cells that can be divided into totipotent stem cells, pluripotent stem cells, and multipotent stem cells according to their development level and differentiation ability. In 2006, Shinya Yamanaka discovered the induced pluripotent stem cells (iPSCs) that can eliminate ethical controversy of stem cells and can be generated from the patient's own cells. Creative Biolabs, as a pioneer in the field of biotechnology CRO, masters the frontier technologies and is fully competent to support stem cell research for global customers in the pharmaceutical, medical, and institutional industry.

The services are basically divided into two streams, one for basic research on stem cells and the other for the development of stem cell therapy.

Basic Research

Creative Biolabs supports the fundamental research projects about induced pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC). It is worth mentioning that regarding the newly-developing cell therapy tool-organoid, a variety of platforms have been developed for organ development, including cerebral organoid, gastric organoid, and thyroid organoid, which are developed based upon the featured 3D bioprint technology. Furthermore, the stem cell editing techniques deepen the research on stem cell therapy on a genetic level, covering clustered regularly interspaced short palindromic repeat (CRISPR), transcription activator-like effector nuclease (TALEN), and recombinant DNA technology.

Stem Cell Therapy Development

Creative Biolabs can develop stem cell-based therapeutics that are disease-specific and is capable of providing not only iPSC derived immune cell therapy and iPSC derived stem cell therapy services, but also the stem cell facilitated drug discovery (drug screening, toxicity and efficacy analysis, target identification, etc.).

In addition to the above-mentioned services, Creative Biolabs has established disease models with the exclusive STEMODTM disease model platform to help understand the etiology and progression of diverse diseases involving the cardiovascular system, nervous system, and ocular system.

In recent years, basic and clinical researches of stem cells are under rapid development. To date, more than 3,000 clinical trials involving the use of adult stem cells, and 262 phase III clinical trials and above have been documented at the International Clinical Trials Registry Platform (ICTRP), of which the indications cover neurological diseases, cardiovascular diseases, diabetes, blood diseases, and cancer. However, many challenges still need to be resolved before stem cells can be used in cell therapy. Creative Biolabs can be a reliable partner to support the corresponding research cases.

More details can be found at https://www.creative-biolabs.com/stem-cell-therapy.

About Creative Biolabs

Creative Biolabs keeps pace with the most up-to-date technologies, handling the projects from global customers who are working on the development of novel therapeutics. After years of exploration and accumulation, a comprehensive system of stem cell therapy development has been established, which is operated by a group of P.h.D level scientists. Dozens of successful cases and regular customers prove the strengths of Creative Biolabs.

Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-619-7922Country: United StatesWebsite: https://www.creative-biolabs.com/stem-cell-therapy

Read the original here:
For Research Only Creative Biolabs Stem Cell Therapy Development Solutions - Press Release - Digital Journal

Posted in Cell Therapy | Comments Off on For Research Only Creative Biolabs Stem Cell Therapy Development Solutions – Press Release – Digital Journal

Stem Cell Therapy Market Size, Growth, Demand, Opportunities & Forecast To 2025 – Cheshire Media

Posted: November 27, 2020 at 9:49 am

The Global Stem Cell Therapy Market Report, 2020-25 is a direct informative document containing important data across both historical and current timelines, providing report readers with an innovative understanding of optimizing business discretion for stable revenue generation and global sustainability. The report is carefully contrasted to cover all important aspects of market development in order to continually enhance the vitality of participants and encourage unbiased market decisions amid the fierce competition in the global Stem Cell Therapy Market. Features such as market specific expansion interests and subsequent developments, analysis of market size by value and size, evaluation of additional factors such as drivers, threats, challenges and opportunities are thoroughly relaxed in this illustrative report provided to optimize business discretion

Sample PDF Brochure with Covid-19 Updates @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

The report on the global Stem Cell Therapy Market sets up a detailed overview with relevant references to the market dynamics. Extensive references to the market segment organized by market type and application have been extensively discussed in the report. The volume and value-based growth estimates of the market have been detailed in the report. This section of the report has thoroughly covered a close review of market trends, popular events and recent developments. In addition, in the report, readers also provide crucial details on sub-segments to ensure high-end growth.

Access full research report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

COVID-19 Specific Analysis: Global Stem Cell Therapy Market

This sophisticated presentation of the global Stem Cell Therapy Market also includes excerpts from pre- and post-COVID-19 assessments that have made a huge difference in the spectrum of market dynamics. This report is designed to fit the readers preferences and to break away from the downward growth process. In this section, we have scrutinized all the important factors and developments that coincide in the global Stem Cell Therapy Market to enable new investment decisions.

The Stem Cell Therapy Market report is thoroughly structured to include the development of significant milestones in the competitive spectrum, highlighting high-end market players with a thorough guide to their core competencies and investment skills while enhancing competition. The research elements presented in this advanced report have been prepared to ensure smooth decision-making based on thorough and unbiased research practices.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Key questions answered in the report:

What are the major developments influencing the global Stem Cell Therapy Market and growth?What is the impact of global Stem Cell Therapy Market development on industry and market participants in the near and far future?What types of global Stem Cell Therapy Market are evolving?What are the evolving applications of the global Stem Cell Therapy Market?What are the key characteristics that will influence the global Stem Cell Therapy Market growth during the study period?Who are the major global players operating in the market?How are the key players using it in the existing global Stem Cell Therapy Market situation?

Key topics covered in this report:

1. Research scope2. Summary3. Stem Cell Therapy Market size by manufacturer4. Regional production5. Consumption by region6. Stem Cell Therapy Market size by type7. Stem Cell Therapy Market size by application8. Manufacturer Profile9. Production forecast10. Consumption forecast11. Upstream, Industry Chain and Downstream Customer Analysis12. Opportunities and challenges, threats and influencers13. Key results14. Appendix

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read this article:
Stem Cell Therapy Market Size, Growth, Demand, Opportunities & Forecast To 2025 - Cheshire Media

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Market Size, Growth, Demand, Opportunities & Forecast To 2025 – Cheshire Media

Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |…

Posted: November 27, 2020 at 9:49 am

Global Animal Stem Cell Therapy Market

Global Animal Stem Cell Therapy Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Global Animal Stem Cell Therapy market.

Global Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2025. The increasing interest of the individuals in this industry is the major reason for the expansion of this market.

Key Market Players: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics.

Request for Sample Copy of this report: (SPECIAL OFFER: UP TO 25% DISCOUNT FOR A LIMITED TIME)

https://www.theresearchinsights.com/request_sample.php?id=284577

Market Segmentation by Types:

Dogs

Horses

Others

Market Segmentation by Applications:

Veterinary Hospitals

Research Organizations

Additionally, the market report has a devoted segment covering the current market players from the Global Animal Stem Cell Therapy Market. A concise profile section similarly fuses the business system and capital-related information so that capital-related decisions can be recommended to the clients effectively.

Buy Exclusive Report:

https://www.theresearchinsights.com/checkout?id=284577

Important Facts about Global Animal Stem Cell Therapy Market Report:

This research report encompasses Global Animal Stem Cell Therapy Market overview, market share, demand and supply ratio, supply chain analysis, and import/export details.

The report has different approaches and procedures endorsed by Key Market players that enable efficient business decisions.

The report offers information such as production value, strategies adopted by market players and products/services they provide.

Click Below to Get Full Report and Related Details:https://www.theresearchinsights.com/reports/COVID19-Version-Global-Animal-Stem-Cell-Therapy-Market-Status-20152019-and-Forecast-20202025-by-Region-Product-TypeEndUse-284577

What Our Report Offers:

Market share valuations of the segments on country and global level

Share analysis of the major market players

Opportunities for new market entrants

Market forecast for a minimum of 6 years for all the segments, sub-segments in various countries and regions

Market Trends (drivers, restraints, opportunities, threats, challenges, investment opportunities, and approvals)

Strategic endorsements in key business segments on the basis of market valuations

Competitive scenario mapping the key development patterns.

Company profiling with comprehensive strategies, financial details, and recent progressions.

Supply chain trends representing the latest technological advancements.

About us:

The Research Insights is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. The Research Insights offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials, and much more.

Contact us:

Robin (Head of Sales) The Research Insights

Phone: +91-996-067-0000 | +44-753-718-0101 | +1-312-313-8080

[emailprotected] | https://www.theresearchinsights.com

Continued here:
Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |...

Posted in Cell Therapy | Comments Off on Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |…

Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 Billion – GlobeNewswire

Posted: November 27, 2020 at 9:49 am

Dublin, Nov. 27, 2020 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

In a Major Setback to the Healthcare System, Non-COVID-19 Care Delivery Bears the Brunt of the Pandemic. Gene Therapy Market Slumps by -13.6%

The global market for Gene Therapy is expected to decline by -13.6% in the year 2020 and thereafter recover and grow to reach US$3.3 billion by the year 2027, trailing a post COVID-19 CAGR of 19.5% over the analysis period 2020 through 2027.

Governments worldwide are focusing all healthcare resources on fighting the global pandemic. Billions of dollars have poured into researching COVID-19 drugs, therapies and vaccines. Over US$8 billion globally excluding the U.S. has been pledged only for vaccine development. The U.S. has independently pumped billions of dollars into COVID-19 research and response. The massive reallocation of funds and reprioritization of efforts has left a glaring gap in other sectors of healthcare.

Gene therapy which holds promise for treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia & AIDS, is slumping due to lack of research funds & reduced footfall of patients seeking treatment. Given the complex and fragile manufacturing and delivery system along with funding models of the industry, COVID-19 has emerged as a black swan event. Various players still find it challenging to ensure timely delivery of gene therapy to patients and clinical sites.

There are concerns regarding administration of cell and gene therapies. The chances of virus transmission, mainly to people in the high-risk group, coerced hospitals to delay or cancel appointments. In addition, travel restrictions and stay-at-home orders discouraged patients from visiting to treatment centers. Treatments intended to be delivered into ICUs are being impacted by bed reservations made for patients with COVID-19 infection.

R&D and preclinical activities are also affected by supply shortages as a result of strong demand for consumables like reagents and PPE from COVID-19 laboratories. The clinical development segment suffered the most due to concerns regarding recruitment of patients and suspension of trial enrollments for protecting participants from the risk of infection. These issues are delaying activation of new sites, prompting players to postpone new clinical trials.

However, the intensity of disruptions for cell and gene therapy trials was less in comparison to the pharmaceutical industry due to association of the former with rare and serious medical conditions, enabling participants to continue trials. While companies targeting paediatric diseases suspended trials, others dealing with oncology maintained the pace. COVID-19 has also impacted patient assessment and has made it difficult for companies to perform follow-up evaluations for trial participants. These issues are attributed to confluence of various factors like travel ban, withdrawal of several services from healthcare sites and the risk of virus transmission.

In addition, these disruptions are anticipated to threaten existence of certain cell and gene therapy companies, particularly small-scale biotech players that are in pre-commercial phase and rely on external funding. As governments, stakeholders, pharmaceutical companies and venture capitalists invest in these players on the basis of research milestones, pipeline progress and data readouts, ability of these companies to secure future funding will also be affected.

In the post COVID-19 period, growth will be led by therapy indications in the field of oncology. Gene therapies hold promise to improve the condition of patients where traditional cancer treatments such as radiation and chemotherapy are not effective. Blood and lymphatic cancers hold huge potential as gene therapies can manipulate the genetic information to target the cancerous proteins, thereby enabling the body to fight against the cancers. Oncology will remain the key area of focus for gene therapy applications. Cancer therapies represent the leading category, as is gauged through robust rise in the number of molecules being tested across numerous clinical trials.

Novartis which recently bagged the U.S. FDA approval for Kymriah, a gene therapy designed for the treatment of hematological cancer, is seeking to gain commercial approval in established and emerging countries. Similarly, Kite Pharma, the developer of YESCARTA, the first CAR T-cell therapy approved for certain types of non-Hodgkin lymphoma in adults, has formed a separate team to provide end-to-end support for its Yescarta customers including hospitals and clinics. Such efforts by developers would augment the use case of gene therapies in treatment of large B-cell lymphoma and acute lymphoblastic leukemia (ALL), the high potential cancer treatment verticals.

More developmental focus will also be shed on monogenic rare diseases which have clearer genomic targets and the unmet need in smaller patient populations. Majority gene therapies so far have come to market through accelerated review pathways of regulatory authorities. In the year 2018 alone, over 150 applications for investigational new drugs for gene therapies were filed.

In the coming years, there will be significant improvement in the number of approvals for new gene therapies. The growth is anticipated to emerge from different modalities including RNAi, ASOs and CRISPR gene editing based therapeutics which offer long term opportunities for growth. These technologies are generating much excitement for investors.

Competitors identified in this market include, among others:

Key Topics Covered:

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

For more information about this report visit https://www.researchandmarkets.com/r/x4ed1e

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More:
Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 Billion - GlobeNewswire

Posted in Cell Therapy | Comments Off on Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 Billion – GlobeNewswire

Jared Wareham: Are Balanced Trait Genetics a Long-Term Answer? – Drovers Magazine

Posted: November 25, 2020 at 11:58 pm

Genetic progress has helped drive our industry forward and each segment along the value chain hasbenefited from technological advancements in genetics followed by breeder integration. But, have we moved the needle far enough with regard to total beef system profitability?

There are opportunities to take a step forward from the current one size fits all production models. Managers are seeking solutions to their constant struggle to balance getting cows bred while producing highly desirable feeder cattle. Any direction a manager leans, maternal or terminal, tends to leave them in a profitability-strapped state. Have balanced trait idealisms taken us as far as they can? Is it time to consider terminal breeding systems?

Frankly, average cow productivity simply isnt good enough to sustain profitability in most systems long-term. There is a real need for advancements in maternal productivity. Highly functional cows that last longer are simply hard to make while also trying to blend the genetics required for terminal performance.

If we truly believe in sustainable production moving forward, this must be accounted for in the environmental equation that supports progress in all areas. Therefore, is it time to examine the feasibility of focused maternal genetic inputs matched with a terminal genetic line to maximize heterosis and metric specific performance traits?

Moreover, why continue to fight the genetic balancing battle while simultaneously struggling with regional environmental challenges and other competing profit centers? If a tiger stripe is the Cadillac of your area, cultivate internal or external pipelines that will meet annual replacement rates. After that, simply use targeted terminal crosses to maximize value-based marketability. The same can be said for every region from coast to coast.

If large ranching systems coast to coast begin this transition into more defined approaches to production with clear efforts toward highly simplified maternal and terminal genetic lines, is that a step backward? Or, does it represent true progress in system processes that will ultimately drive successful ranching? I think it might be the next logical step. A transition made possible by technologies such as sexed semen and other advancements in genetics and forced by growing challenges to operational efficiencies.

It might represent a form of production that is simply a generation newer. Perhaps the time has come to finally effectively utilize purpose specific lines of genetics to achieve sustainable levels of profit through the right combination of simplicity and precision. Balanced trait genetic approaches have brought the national beef herd to the great place it is today. However, will its overarching effectiveness continue to diminish as our industry progresses?

Jared Wareham is the North American business development manager for ABS NuEra. He has been involved in the cattle industry for over two decades, in business development roles growing genetics-focused companies that service producers along the beef value chain by driving the integration of precision-based production.

More here:
Jared Wareham: Are Balanced Trait Genetics a Long-Term Answer? - Drovers Magazine

Posted in Genetics | Comments Off on Jared Wareham: Are Balanced Trait Genetics a Long-Term Answer? – Drovers Magazine

Turbo Charging the Genetic Stocks Contained in the Worlds Seed Banks – Technology Networks

Posted: November 25, 2020 at 11:58 pm

Seed banks across the globe store and preserve the genetic diversity of millions of varieties of crops. This massive collection of genetic material ensures crop breeders access to a wealth of genetics with which to breed crops that yield better or resist stress and disease.

But, with a world of corn genetics at their disposal, how do plant breeders know which varieties are worth studying and which ones aren't? For most of history, that required growing the varieties and studying their performance in the real world. But innovative data analytics and genomics could help plant breeders predict the performance of new varieties without having to go to the effort of growing them.

Jianming Yu, a professor of agronomy at Iowa State University and the Pioneer Distinguished Chair in Maize Breeding, has devoted much of his research to "turbo charging" the seemingly endless amount of genetic stocks contained in the world's seed banks. Yu and his colleagues have published an article in the Plant Biotechnology Journal, a scientific publication, that details their latest efforts to predict traits in corn-based on genomics and data analytics.

Plant breeders searching for varieties to test might feel lost in a sea of genomic material. Yu said applying advanced data analytics to all those genomes can help breeders narrow down the number of varieties they're interested in much faster and more efficiently.

"We're always searching for the best genetic combinations, and we search the various combinations to see what varieties we want to test," said Xiaoqing Yu (no relation), a former postdoctoral research associate in Yu's lab and the first author of the study. "Having these predictions can guide our searching process."

The study focused on predicting eight corn traits based on the shoot apical meristem (SAM), a microscopic stem cell niche that generates all the above-ground organs of the plant. The researchers used their analytical approach to predict traits in 2,687 diverse maize inbred varieties based on a model they developed from studying 369 inbred varieties that had been grown and had their shoot apical meristems pictured and measured under the microscope.

The researchers then validated their predictions with data obtained from 488 inbreds to determine their prediction accuracy ranged from 37% to 57% across the eight traits they studied.

"We wanted to connect the research in foundational biological mechanisms of cell growth and differentiation with agronomic improvement of corn," said Mike Scanlon, a professor of developmental biology at Cornell University and the lead investigator of the multi-institutional team behind the study. "SAM morphometric measurements in corn seedlings allow a quick completion of the study cycle. It not only enables that connection, but also extends the practice of genomic prediction into the microphenotypic space."

Jianming Yu said plant breeders can bump up the accuracy of those genomic predictions by increasing the number of plants per inbred for measurement and findings-improved prediction algorithms. More importantly, plant breeders can finetune their selection process for which inbreds to study closely by leveraging the "U values," a statistical concept that accounts for the reliability of estimates. Yu said the study shows that implementing a selection process that accounts for prediction and statistical reliability can help plant breeders zero in on desirable crop genetics faster.

For instance, analytical models might predict a particular inbred to have modest potential for a given trait, but the U value, or the upper bound for reliability, might indicate a high degree of unreliability in those predictions. So plant breeders might elect to test inbreds that don't do as well in the predictive model simply because of their genetic uniqueness, being less related to those used in building the prediction models.

"We found that there can be a balance between selecting for optimizing short-term gain and mining diversity," Yu said. "It's a tricky balance for plant breeders. Those considerations sometimes go in different directions. Genetic improvement can be viewed as space exploration, either of the vast amount of existing genetic materials in seed banks or of the innumerable breeding progenies constantly being generated. We want to develop better tools to guide those decisions in the process."

Reference: Yu X, Leiboff S, Li X, et al.Genomic prediction of maize microphenotypes provides insights for optimizing selection and mining diversity.Plant Biotechnol. J. 2020. doi:10.1111/pbi.13420

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to see the original:
Turbo Charging the Genetic Stocks Contained in the Worlds Seed Banks - Technology Networks

Posted in Genetics | Comments Off on Turbo Charging the Genetic Stocks Contained in the Worlds Seed Banks – Technology Networks

Page 819«..1020..818819820821..830840..»